Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Nkarta Inc Market Cap
From what 0 stock analysts predict, the share price for Nkarta Inc (NKTX) might increase by 228.84% in the next year. This is based on a 12-month average estimation for NKTX. Price targets go from $13 to $22. The majority of stock analysts believe NKTX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Nkarta Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Nkarta Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of NKTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Emily Bodnar HC Wainwright & Co. | Buy | $22 | Maintains | Aug 15, 2024 |
| Gil Blum Needham | Buy | $13 | Reiterates | Aug 14, 2024 |
| Laura Prendergast Raymond James | Strong Buy | $16 | Upgrade | Aug 14, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $23 | Reiterates | Jul 24, 2024 |
| Gil Blum Needham | Buy | $13 | Reiterates | Jun 28, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $23 | Reiterates | Jun 27, 2024 |
| Gil Blum Needham | Buy | $13 | Maintains | May 13, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $23 | Maintains | May 13, 2024 |
| Bill Maughan Canaccord Genuity | Buy | $15 | Maintains | May 10, 2024 |
| Gil Blum Needham | Buy | $15 | Reiterates | Apr 10, 2024 |
| Bill Maughan Canaccord Genuity | Buy | $16 | Maintains | Mar 26, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $22 | Maintains | Mar 25, 2024 |
| Salim Syed Mizuho | Buy | $25 | Maintains | Mar 22, 2024 |
| Laura Prendergast Raymond James | Outperform | $16 | Downgrade | Mar 22, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $20 | Maintains | Mar 22, 2024 |
| Gil Blum Needham | Buy | $15 | Reiterates | Mar 22, 2024 |
| Salim Syed Mizuho | Buy | $31 | Maintains | Mar 5, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $22 | Maintains | Jan 16, 2024 |
| Gil Blum Needham | Buy | $15 | Reiterates | Dec 12, 2023 |
| Salim Syed Mizuho | Buy | $9 | Maintains | Nov 16, 2023 |
When did it IPO
2020
Staff Count
150
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Paul J. Hastings
Market Cap
$380.3M
In 2023, NKTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NKTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 18 Oct 2023
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.
Tue, 17 Oct 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - NEW YORK , Oct. 17, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory services and will support Nkarta in early development through select sites of the Lupus Clinical Investigators Network (LuCIN) comprised of top academic centers throughout North America.
Tue, 17 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy
Mon, 16 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m.
Mon, 02 Oct 2023
Sentiment - POSITIVE
Source - InvestorPlace
Summary - For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
Thu, 10 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
